| pubmed-article:19584291 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19584291 | lifeskim:mentions | umls-concept:C0527443 | lld:lifeskim |
| pubmed-article:19584291 | lifeskim:mentions | umls-concept:C0206686 | lld:lifeskim |
| pubmed-article:19584291 | lifeskim:mentions | umls-concept:C0521428 | lld:lifeskim |
| pubmed-article:19584291 | lifeskim:mentions | umls-concept:C0596290 | lld:lifeskim |
| pubmed-article:19584291 | lifeskim:mentions | umls-concept:C0597513 | lld:lifeskim |
| pubmed-article:19584291 | pubmed:issue | 14 | lld:pubmed |
| pubmed-article:19584291 | pubmed:dateCreated | 2009-7-16 | lld:pubmed |
| pubmed-article:19584291 | pubmed:abstractText | Bone morphogenetic proteins (BMP) have been shown to affect tumorigenesis in a variety of tumors. Quantitative PCR analysis revealed down-regulation of BMP2 and BMP5 in tissue samples from adrenocortical carcinoma and adrenocortical tumor cell lines compared with normal adrenal glands. Integrity of BMP-dependent pathways in these cell lines could be shown by activation of the Smad1/5/8 pathway with subsequent increase of ID protein expression upon incubation with BMP2 or BMP5. On a functional level, BMP treatment resulted in inhibition of cell proliferation and viability in a dose- and time-dependent manner. This growth inhibitory effect was associated with BMP-dependent reduction of AKT phosphorylation under baseline conditions and under insulin-like growth factor costimulation. Furthermore, steroidogenic function, including melanocortin-2 receptor and steroidogenic enzyme expressions, was profoundly reduced. In vitro demethylation treatment and overexpression of GATA6 resulted in reactivation of BMP-dependent pathways with concomitant modulation of steroidogenesis. Taken together, we show that loss of expression of members of the BMP family of ligands is a common finding in adrenocortical tumors and we provide evidence that BMP-dependent pathways are likely to be involved in the modulation of the malignant and functional phenotype of adrenocortical cancer cells. | lld:pubmed |
| pubmed-article:19584291 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19584291 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19584291 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19584291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19584291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19584291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19584291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19584291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19584291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19584291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19584291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19584291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19584291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19584291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19584291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19584291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19584291 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19584291 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:19584291 | pubmed:issn | 1538-7445 | lld:pubmed |
| pubmed-article:19584291 | pubmed:author | pubmed-author:BeuschleinFel... | lld:pubmed |
| pubmed-article:19584291 | pubmed:author | pubmed-author:KapplerRoland... | lld:pubmed |
| pubmed-article:19584291 | pubmed:author | pubmed-author:AuernhammerCh... | lld:pubmed |
| pubmed-article:19584291 | pubmed:author | pubmed-author:JohnsenInga... | lld:pubmed |
| pubmed-article:19584291 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19584291 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:19584291 | pubmed:volume | 69 | lld:pubmed |
| pubmed-article:19584291 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19584291 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19584291 | pubmed:pagination | 5784-92 | lld:pubmed |
| pubmed-article:19584291 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:meshHeading | pubmed-meshheading:19584291... | lld:pubmed |
| pubmed-article:19584291 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19584291 | pubmed:articleTitle | Bone morphogenetic proteins 2 and 5 are down-regulated in adrenocortical carcinoma and modulate adrenal cell proliferation and steroidogenesis. | lld:pubmed |
| pubmed-article:19584291 | pubmed:affiliation | Departments of Medicine, University Hospital Innenstadt, Ludwig Maximilians University, Munich, Germany. | lld:pubmed |
| pubmed-article:19584291 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19584291 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:650 | entrezgene:pubmed | pubmed-article:19584291 | lld:entrezgene |
| entrez-gene:653 | entrezgene:pubmed | pubmed-article:19584291 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:19584291 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:19584291 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19584291 | lld:pubmed |
